By Sherri Oslick --
About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Cephalon Inc. v. Mylan Pharmaceuticals Inc. et al.
1:12-cv-00073; filed January 24, 2012 in the District Court of Delaware
• Plaintiff: Cephalon Inc.
• Defendants: Mylan Pharmaceuticals Inc.; Mylan Inc.
Cephalon Inc. v. Sandoz Inc.
1:12-cv-00074; filed January 24, 2012 in the District Court of Delaware
The complaints in these cases are substantially identical. Infringement of U.S. Patent No. 8,092,832 ("Generally Linear Effervescent Oral Fentanyl Dosage Form and Methods of Administering," issued January 10, 2012) in conjunction with Mylan's prior filing of an ANDA to manufacture a generic version of Cephalon's Fentora® (fentanyl citrate buccal tablets, used to treat breakthrough pain in adult patients with cancer). View the Mylan complaint here.
Abbott Laboratories et al. v. Cadila Healthcare Ltd. et al.
1:12-cv-00065; filed January 20, 2012 in the District Court of Delaware
• Plaintiffs: Abbott Laboratories; Abbott Respiratory LLC
• Defendants: Cadila Healthcare Ltd. d/b/a Zydus Cadila; Zydus Pharmaceuticals (USA) Inc.
Infringement of U.S. Patent No. 6,080,428 ("Nicotinic Acid Compositions for Treating Hyperlipidemia and Related Methods Therefor," issued June 27, 2000) following a Paragraph IV certification as part of Zydus' filing of an ANDA to manufacture a generic version of Abbott's Niaspan® (niacin extended-release tablets, used to treat hypercholesterolemia). View the complaint here.
Eli Lilly and Company v. Accord Healthcare, Inc., USA
1:12-cv-00086; filed January 20, 2012 in the Southern District of Indiana
Infringement of U.S. Patent No. 7,772,209 ("Novel Antifolate Combination Therapies," issued August 10, 2010) following a Paragraph IV certification as part of Accord's filing of an ANDA to manufacture a generic version of Lilly's Alimta® (pemetrexed for injection, used to treat malignant pleural mesothelioma and locally advanced or metastatic non-small cell lung cancer). View the complaint here.
Spectrum Pharmaceuticals, Inc. et al v. Sandoz Inc.
2:12-cv-00111; filed January 20, 2012 in the District Court of Nevada
• Plaintiffs: Spectrum Pharmaceuticals, Inc.; University of Strathclyde
• Defendant: Sandoz Inc.
Infringement of U.S. Patent No. 6,500,829 ("Substantially Pure Diastereoisomers of Tetrahydrofolate Derivatives," issued December 31, 2002) following a Paragraph IV certification as part of Sandoz's filing of an ANDA to manufacture a generic version of Spectrum's Fusilev® (levoleucovorin, used to treat advanced metastatic colorectal cancer). View the complaint here.
Meda Pharmaceuticals Inc. v. Apotex Inc. et al.
3:12-cv-00361; filed January 19, 2012 in the District Court of New Jersey
• Plaintiff: Meda Pharmaceuticals Inc.
• Defendants: Apotex Inc.; Apotex Corp.; Perrigo Co.; L. Perrigo Co.; Perrigo Israel Pharmaceutical Ltd.
Infringement of U.S. Patent No. 8,071,073 ("Compositions Comprising Azelastine and Methods of Use Thereof," issued December 6, 2011) following a Paragraph IV certification as part of defendants' filing of an ANDA to manufacture a generic version of Meda's Astepro® (azelastine hydrochloride nasal spray, used to treat hay fever and allergy symptoms). View the complaint here.
Comments